Alphaxalone
Especificaciones
23930-19-0Número CAS
636-625-6Número CE
(3R,5S,8S,9S,10S,13S,14S,17S)-17-acetyl-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-11-oneNombre IUPAC
C21H32O3Fórmula química
332.5 g/molPeso molecular
Alfaxalone; Alphaxalone; 23930-19-0; Alphaxolone; Alfaxalona; Alfaxalonum; Phaxan; 3alpha-Hydroxy-5alpha-pregnane-11,20-dione; GR 2/234; DTXSID9022576; Alfadione; BD07M97B2A; (3R,5S,8S,9S,10S,13S,14S,17S)-17-acetyl-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-11-one; GR-2/234; alfaxolone; DTXCID702576; delta(16)-alfaxalone; Alfaxan; Alfaxan Multidose; (3R,5S,8S,9S,10S,13S,14S,17S)-17-acetyl-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,12,14,15,16,17-tetradecahydrocyclopenta(a)phenanthren-11-one; hydroxy-5 alpha-pregnane-11,20-dione; RefChem:57111; ALFAXAN MULTIDOSE IDX; N01AX05; 5alpha-Pregnan-3alpha-ol-11,20-dione; Alfaxalonum [INN-Latin]; Alfaxalona [INN-Spanish]; MLS000069684; MLS001076262; CHEMBL190279; Alfaxalone (INN); 3-Hydroxypregnane-11,20-dione; Alfaxalone; Alphaxalone; NCGC00023100-03; SMR000058494; (3a,5a)-3-Hydroxypregnane-11,20-dione; ALFAXALONE [INN]; SR-01000000168; BRN 3217240; UNII-BD07M97B2A; 3alpha-Hydroxy-5alpha-pregnan-11,20-dion; 5alpha-alphaxalone; Alfaxalone [INN:BAN:DCF:JAN]; 3-alpha-Hydroxy-5-alpha-pregnane-11,20-dione; (3-alpha,5-alpha)-3-Hydroxypregnane-11,20-dione; CAS-23930-19-0; ALFAXALONE [MI]; 3.alpha.-Hydroxy-5.alpha.-pregnane-11,20-dione; ALFAXALONE [JAN]; Opera_ID_1629; Prestwick0_001002; Prestwick1_001002; Prestwick2_001002; Prestwick3_001002; ALFAXALONE [MART.]; ALFAXALONE [WHO-DD]; BIDD:PXR0037; Lopac0_000929; Pregnane-11,20-dione, 3-hydroxy-, (3a,5a)-; SCHEMBL57756; BSPBio_001123; 4-08-00-02091 (Beilstein Handbook Reference); 5-alpha-Pregnane-11,20-dione, 3-alpha-hydroxy-; SPBio_003004; BPBio1_001237; GTPL5461; ALFAXALONE [GREEN BOOK]; CHEBI:34531; Pregnane-11,20-dione, 3-hydroxy-, (3-alpha,5-alpha)-; HMS1571I05; HMS2098I05; HMS2236N05; HMS3262J20; HMS3715I05; MSK14604; Tox21_110884; Tox21_500929; BDBM50164570; AKOS024457399; Tox21_110884_1; CCG-205010; DB11371; LP00929; SDCCGSBI-0050903.P002; 5alpha-pregnane-3alpha-ol-11,20-dione; NCGC00023100-04; NCGC00023100-05; NCGC00023100-06; NCGC00023100-08; NCGC00261614-01; AB00384358; EU-0100929; NS00067930; D07282; P 5052; (3alpha,5alpha)-3-hydroxypregnane-11,20-dione; SR-01000076070; Q3611058; SR-01000000168-2; SR-01000000168-3; SR-01000076070-1; BRD-K41445866-001-03-0; BRD-K41445866-001-18-8; 5alpha-Pregnan-3alpha-ol-11,20-dione, powder, >=98% (TLC); (3beta,5alpha,8alpha,9beta,10alpha)-3-hydroxypregnane-11,20-dione; (3R,5S,8S,9S,10S,13S,14S,17S)-17-Acetyl-3-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-11-one; EY4Sinónimos
